treatment options for high-risk aml
Published 4 years ago • 417 plays • Length 5:01Download video MP4
Download video MP3
Similar videos
-
1:59
assessing if a patient with dlbcl is responding to treatment using pet-ct and novel assays
-
1:21
trends in allosct for good-risk aml: a longitudinal study
-
3:47
the impact of cytogenetic-risk stratification on aml outcomes
-
1:09
menin inhibitors for the treatment of aml: insights into the covalent-101 trial
-
3:40
how the aml treatment landscape has evolved with the use of novel combination therapies
-
1:41
the importance of integrating genomic and cytogenetic data in treatment decisions for aml
-
2:14
a new classification for identifying high-risk myeloma based on cytogenetic abnormalities
-
9:25
mgus diagnosis: a step-by-step approach
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
5:11
the frontline treatment strategy for newly diagnosed aml
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
2:36
treatment approaches to cll with high-risk molecular features
-
2:57
the importance of analyzing cytogenetic risk in patients with aml undergoing haploidentical sct
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
14:43
current research into post-allosct maintenance therapy in aml
-
1:19
new treatments for aml
-
2:11
efficacy of parp inhibitors in the treatment of aml
-
1:17
combination therapy for the treatment of aml
-
2:25
analyzing aml: novel therapies in review
-
1:23
new treatments for aml using inhibitors